Relation of Serum Paraoxonase-1 Activity with Brachial Artery Intima Media Thickness in Obese Versus Non-Obese Diabetic Patients

Program: Abstracts - Orals, Poster Previews, and Posters
Session: FRI 586-617-Cardiovascular Risk
Friday, March 6, 2015: 1:00 PM-3:00 PM
Hall D-F, Diabetes (San Diego Convention Center)

Poster Board FRI-593
Pinar Karakaya1, Meral Mert2, Yildiz Okuturlar2, Asuman Gedikbasi2, Filiz Islim2, Didem Acarer2, Nursel Kocamaz2, Ozlem Soyluk2, Teslime Ayaz3, Pinar Alarslan4, Ozlem Harmankaya2 and Abdulbaki Kumbasar2
1Bakirkoy Dr. Sadi Konuk Training and Research Hospital, Istanbul, 2Bakirkoy Dr. Sadi Konuk Training and Research Hospital, Istanbul, Turkey, 3Recep Tayyip Erdogan University Training and Research Hospital, Rize, Turkey, 4Katip Celebi University Ataturk Training and Research Hospital, Izmir, Turkey
Human paraoxonase 1/arylesterase (PON1) is a calcium dependent ester hydrolase with paraoxonase, arylesterase and diazoxonase activities along with antioxidant and anti-atherogenic properties (1-3). Decrease in PON1 activity was documented in states of high oxidative stress like metabolic syndrome, obesity, uncontrolled diabetes, and dyslipidemia and shown to be associated with susceptibility to coronary artery disease (1,4). This study was designed to evaluate the relation of serum paraoxonase and arylesterase activities with biochemical variables and brachial artery diameter (BAd) and intima media thickness (BA-IMT) in obese versus non-obese diabetic patients. A total of 201 diabetic patients were included in the present study as divided into two groups including obese (n=89, patients with BMI>30kg/m2, mean±SD age: 52.8(11.7) years, 83.1% were females) and non-obese (n=82, BMI<29.99 kg/m2, mean±SD age: 52.2(14.6) years, 65.5% were females) diabetic patients. Data on patient characteristics, blood biochemistry, HOMA-IR, BAd and BA-IMT were evaluated along with serum paraoxonase and arylesterase activities. No significant difference was noted in mean±SD paraoxonase (119.5±35.6 U/L in the obese group and 120±39.1 U/L in the non-obese group) and arylesterase values (150.4±39.0 U/L in the obese group and 147.9±40.7 U/L in the non-obese group) with respect to obesity. Paraoxonase and arylesterase activities were negatively correlated with HbA1c (r=-0.533, p=0.000 and r=-0.544, p=0.000, respectively) and plasma glucose (r=-0.457, p=0.000 and r=-0.584, p=0.000, respectively) in the overall study population as were in obese and non-obese groups. There was a negative correlation of HOMA-IR to paraoxonase (r=-0.263, p=0.039 in obese and r=-0.281, p=0.007 in non-obese patients) and arylesterase (r=-0.269, p=0.035 in obese and r=-0.334, p=0.001 in non-obese patients) levels in both obese and non-obese patients. Except for negative correlation of arylesterase (r=-0.303, p=0.048) and paraoxonase (r=-0.340, p=0.026) to left BA-IMT in obese patients, no correlation of paraoxonase and arylesterase values was noted to BAd and BA-IMT. In conclusion, our findings revealed no difference in serum paraoxonase and arylesterase activities with respect to obesity, gender and age along with a negative correlation of both serum paraoxonase and arylesterase activities to plasma glucose, HbA1c and HOMA-IR in both obese and non-obese patients, while to left BA-IMT only in obese diabetic patients. In this regard, our findings emphasize the possible role of low serum paraoxonase and arylesterase activities in predicting poor glycemic control among diabetics regardless of obesity, whereas early atherosclerosis only in obese diabetic patients.

(1) Kota SK, et al. Implications of serum paraoxonase activity in obesity, diabetes mellitus, and dyslipidemia. Indian J Endocrinol Metab 2013;17:402-412.  (2) Mastorikou M, et al. Defective metabolism of oxidised-phospholipid by high-density lipoprotein from people with type 2 diabetes. Diabetes 2006;55:3099-3103. (3) Haffner SM, et al. Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction. N Engl J Med 1998;339:229-234. (4) Mackness B, et al. Serum paraoxonase (PON1) 55 and 192 polymorphism and paraoxonase activity and concentration in non-insulin dependent diabetes mellitus. Atherosclerosis 1998;139:341-349.

Nothing to Disclose: PK, MM, YO, AG, FI, DA, NK, OS, TA, PA, OH, AK

*Please take note of The Endocrine Society's News Embargo Policy at